Mamouch F, Berrada N, Aoullay Z, et al. Inflammatory Breast Cancer: A Literature Review. World J Oncol 2018;9(5-6):129-35.
Aurit SJ, Devesa SS, Soliman AS, et al. Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015). Breast Cancer Res Treat 2019;175(3):755-64.
Adesoye T, Irwin S, Sun SX, Lucci A, Teshome M. Contemporary surgical management of inflammatory breast cancer: a narrative review. Chin Clin Oncol 2021;10(6):57.
Van Uden DJP, van Laarhoven HWM, Westenberg AH, et al. Inflammatory breast cancer: An overview. Crit Rev Oncol Hematol 2015;93(2):116-26.
Biswas T, Jindal C, Fitzgerald TL, et al. Pathologic complete response (pCR) and survival of women with inflammatory breast cancer (IBC): An analysis based on biologic subtypes and demographic characteristics. Int J Environ Res Public Health 2019;16(1).
Chainitikun S, Mingmalairak S, Parinyanitikul N. What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review. Chin Clin Oncol 2021;10(6):55.
Zhang Y, Xu Z, Chen H, et al. Survival comparison between postoperative and preoperative radiotherapy for stage I–III non-inflammatory breast cancer. Sci Rep 2022;12(1).
Van Uden DJP, van Maaren MC, Strobbe LJA, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Research 2019;21(1).
Liu J, Chen K, Jiang W, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. J Cancer Res Clin Oncol 2017;143(1):161-8.
Kupstas AR, Hoskin TL, Day CN, et al. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. B J Surg 2020;107(8):1033-41.
National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Patel MM, Le-Petross HT. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review. Chin Clin Oncol 2021;10(6):56.
Ueno NT, Espinosa Fernández JR, Cristofanilli M, et al. International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference. J Cancer 2018;9(8):1437-47.
Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(Suppl.2):S69-74.
Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response with Docetaxel. J Clin Oncol 2002;20(6):1456-66.
Shao N, Wang S, Yao C, et al. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials. Breast 2012;21(3):389-93.
Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): An open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol 2014;15(2):201-12.
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(8):1194-220.
Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40(4):321-9.
Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55(5):1200-8.
Baldini E, Gardin G, Evangelista G, et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 2004;5(5):358-63.
Low JA, Berman AW, Steinberg SM, et al. Long-term follow- up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22(20):4067-74.
Cristofanilli M, González-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor-negative inflammatory breast cancer: The M.D. Anderson Cancer Center experience. Clin Breast Cancer 2004;4(6):415-9.
Ditsch N, Vodermaier A, Hinke A, et al. Dose-dense Intensified Sequential Versus Conventionally- dosed Anthracycline and Taxane- containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer. Anticancer Res 2012;3539-45.
Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011;29(8):1014-21.
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33(1):13-21.
Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014;15(7):747-56.
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New Engl J Med 2017;376(22):2147-59.
Reina Sofi H, Gianni L, Pienkowski T, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, infl ammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17(6):791-800.
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline- containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24(9):2278-84.
Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018;89:27-35.
Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018;19(1):115-26.
Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New Engl J Med 2019;380(7):617-28.
Matsuda N, Lim B, Wang X, et al. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs 2017;26(4):463-79.
Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: New insights in the biology of inflammatory breast cancer. Ann Oncol 2007;18(6):1021-9.
Matsuda N, Wang X, Lim B, et al. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol 2018;4(9):1207-13.
Bertucci F, Fekih M, Autret A, et al. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): A multicentre, single-arm, phase 2 study. Lancet Oncol 2016;17(5):600-11.
Pierga JY, Petit T, Delozier T, et al. Articles Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary infl ammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012;13:375-84.
Palazzo A, Dellapasqua S, Munzone E, et al. Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clin Breast Cancer 2018;18(4):328-35.
Mayer EL, Dueck AC, Martin M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2020;22(2):212-22.
Loibl S, Marmé F, Martin M. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B. San Antonio Breast Cancer Symp. Cancer Res 2021;81(Suppl.4):GS1-02.
D Johnston SR, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR1, HER22, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020;38:3987-98.
Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New Engl J Med 2016;375(3):209-19.
Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New Engl J Med 2018;379(2):122-37.
Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 2015;6(15):13506-19.
Van Berckelaer C, Rypens C, van Dam P, et al. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research 2019;21(1).
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline- based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. The Lancet 2020;396(10257):1090-100.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple- Negative Breast Cancer. New Engl J Med 2020;382(9):810-21.
Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell 2021;39(7):989-998.e5.
Loibl S, Schneeweiss A, Huober JB. Durvalumab improves longterm outcome in TNBC: results from the phase II randomized Gepar- NUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 2021;39(15).
Li ZW, Zhang M, Yang YJ, et al. Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: A SEER population-based retrospective study. PeerJ 2020;2020(2).
Orecchia R. Radiation therapy for inflammatory breast cancer. Eur J Surg Oncol 2018;44:1148-50.
Bertucci F, Finetti P, Birnbaum D, et al. Gene expression profiling of inflammatory breast cancer. Cancer 2010;116(Suppl. 11):2783-93.
Bonito M di, Cantile M, Botti G. Pathological and molecular characteristics of inflammatory breast cancer. Transl Cancer Res 2019;8(Suppl.5):S449-S56.
Chakraborty P, George JT, Woodward WA, et al. Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum. Transl Oncol 2021;14(4).
Número de descargas:
16405
Número de visitas:
1836
Citas:
0
